Regulatory-required post-marketing database studies in Japan could be leveraged to assess important potential risks as well as identified risks.
Saved in:
| Title: | Regulatory-required post-marketing database studies in Japan could be leveraged to assess important potential risks as well as identified risks. |
|---|---|
| Authors: | Yamazaki H; Global Epidemiology, Johnson & Johnson, Tokyo, Japan., Nakajo K; Global Epidemiology, Johnson & Johnson, Tokyo, Japan., Hirose N; Global Epidemiology, Johnson & Johnson, Tokyo, Japan., Yan L; Global Epidemiology, Johnson & Johnson, Beijing, China., Lee SY; Global Epidemiology, Johnson & Johnson, Seoul, Republic of Korea., Zhang Y; Global Epidemiology, Johnson & Johnson, Beijing, China., Qiu H; Global Epidemiology, Johnson & Johnson, Titusville, NJ, United States., Ishiguro C; Laboratory of Epidemiology Section, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2025 Jul 21; Vol. 16, pp. 1565314. Date of Electronic Publication: 2025 Jul 21 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2025.1565314 |
